These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15694744)

  • 21. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
    Bennett MT; Johns KW; Bondy GP
    Lipids Health Dis; 2007 Jun; 6():15. PubMed ID: 17565701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
    Jinnouchi Y; Yamagishi S; Takeuchi M; Ishida S; Jinnouchi Y; Jinnouchi J; Imaizumi T
    Clin Exp Med; 2006 Dec; 6(4):191-3. PubMed ID: 17191111
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypertriglyceridemia and hypercholesterolemia: effects of drug treatment on fatty acid composition of plasma lipids and membranes.
    Nyalala JO; Wang J; Dang A; Faas FH; Smith WG
    Prostaglandins Leukot Essent Fatty Acids; 2008; 78(4-5):271-80. PubMed ID: 18502109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank.
    Peissig P; Sirohi E; Berg RL; Brown-Switzer C; Ghebranious N; McCarty CA; Wilke RA
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):286-8. PubMed ID: 17371534
    [No Abstract]   [Full Text] [Related]  

  • 25. Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
    Le Moyec L; Valensi P; Charniot JC; Hantz E; Albertini JP
    NMR Biomed; 2005 Nov; 18(7):421-9. PubMed ID: 16075416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia.
    Tanaka N; Momiyama Y; Ohmori R; Yonemura A; Ayaori M; Ogura M; Sawada S; Kusuhara M; Nakamura H; Ohsuzu F
    Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):e129-30. PubMed ID: 16857954
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF; Kastelein JJ;
    Int J Clin Pract; 2005 Dec; 59(12):1387-94. PubMed ID: 16351669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Studies on HDL-cholesterol in diabetes mellitus (author's transl)].
    Matsuoka Y; Okamoto Y; Umegaki K; Tsujii T; Kubota C
    Rinsho Byori; 1980 Mar; 28(3):244-50. PubMed ID: 7373887
    [No Abstract]   [Full Text] [Related]  

  • 31. Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
    Nováková L; Vlcková H; Satínský D; Sadílek P; Solichová D; Bláha M; Bláha V; Solich P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):2093-103. PubMed ID: 19540175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of hyperlipidemia in diabetes.
    Vinik AI; O'Brian JT; Georges LP; Leichter SB; Janin Y
    Compr Ther; 1995 Oct; 21(10):602-9. PubMed ID: 8565431
    [No Abstract]   [Full Text] [Related]  

  • 34. Apolipoproteins AI and B as therapeutic targets.
    Charlton-Menys V; Durrington P
    J Intern Med; 2006 May; 259(5):462-72. PubMed ID: 16629852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Media report of rare rhabdomyolysis cases seems to have triggered reluctance among some New Zealanders to use statins.
    Gladding PA; Kerr A; Edwards C
    N Z Med J; 2006 Sep; 119(1241):U2159. PubMed ID: 16964305
    [No Abstract]   [Full Text] [Related]  

  • 36. [Dyslipoproteinemia of diabetes: fibrates or statins?].
    Moulin P
    Diabetes Metab; 1999 Sep; 25(3):270-4. PubMed ID: 10499198
    [No Abstract]   [Full Text] [Related]  

  • 37. Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
    de Lorgeril M; Boissonnat P; Salen P; Monjaud I; Dureau G
    J Heart Lung Transplant; 1996 May; 15(5):539-40. PubMed ID: 8771511
    [No Abstract]   [Full Text] [Related]  

  • 38. [Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
    MMW Fortschr Med; 2005 Nov; 147(45):55. PubMed ID: 16320656
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
    Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.